AKT1 and hepatocellular carcinoma: The promotion of SRY in hepatocarcinogenesis is partly attributed to the activation of the SOX9 and PDGFRα/PI3K/Akt pathway, given that these pathways are involved in promoting inflammation, fibrosis, and development of HCC [27,28,29,30].